CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.

ABSTRACT:

Background

Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim of the study was to find new genetic treatment predictive markers of AIs.

Methods

The ongoing population-based BC-blood study in Lund, Sweden includes women with primary breast cancer. This paper is based on AI-treated patients with estrogen receptor positive tumors who underwent breast cancer surgery in 2002-2008. First, an exploratory analysis of 1931 SNPs in 227 genes involved in absorption, distribution, metabolism, and elimination of multiple medications, using DMET™ chips, was conducted in a subset of the cohort with last follow-up in December 31s

SUBMITTER: Simonsson M 

PROVIDER: S-EPMC4815192 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature